Hizentra is the first and only self-administered Ig proven to prevent CIDP relapse, so you and your doctor can fit treatment into your routine.

CIDP indication and usage

Hizentra is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Proven Control

Hizentra is FDA approved and proven to prevent relapse* of CIDP in the largest clinical trial

*Patients withdrew from the study or relapsed less often than those taking placebo

body points

People on Hizentra maintained their:

  • Upper-body strength
  • Grip strength
  • Lower-body strength

Demonstrated Tolerability


of Hizentra infusions were completed without any side effects

The most common side effects were infusion-site reactions, headache, cold, fatigue, upper respiratory infection, fall, back pain, joint pain, and pain in extremity. One serious side effect was also reported: skin rash due to allergies.

3.6x lower

In clinical trials, patients experienced fewer systemic side effects (like headache and nausea) with Hizentra than with IVIg

Flexibility and Freedom


With convenient weekly dosing, Hizentra gives you the power to plan treatment around your life, instead of planning your life around treatment

pill bottles

And you can self-infuse, so you can manage your CIDP effectively on your own schedule

Send this information to my email

Your email address will only be used to send this email and will not be saved or stored.

Start strong

Self-administration can be easy to learn, and with a bit of training you can be infusing at home in no time. See how self-administration training can help you get started on Hizentra.

CIDP control with convenient dosing

Sometimes it can feel like you don’t have control over your CIDP treatment and its impact on your life. That can change with Hizentra.

Hizentra offers convenient self-infusions, so you and your doctor can decide how best to fit your infusions into your weekly routine.

You and your doctor can choose:

  • How much you infuse
  • How fast you infuse
  • Number of infusion sites

IgIQSM: Your single source for Ig support

IgIQ gathers many Ig resources under one roof, making it easy to get the guidance and support you need with a single phone call.

Our friendly and knowledgeable staff can:

  • Answer general (non-medical) questions
  • Provide helpful resources
  • Enroll you in peer support and financial assistance programs
  • Answer questions related to insurance coverage

Learn more about Hizentra for CIDP

Stay in touch! Sign up here for updates.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0520-MAY18